Boardroom Alpha
Start trial
Boardroom Alpha
INKT · Current Report (Form 8-K) · Filed March 27, 2026

Mink Therapeutics Inc — Current Report (Form 8-K)

Form
8-K
Filed
March 27, 2026
Period
Mar 27, 2026
Ticker
INKT
Accession
0001193125-26-127931
Mink Therapeutics Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

MiNK clarifies ongoing discussions with multiple parties on potential agenT-797 combination trials and strategic minority investments; no binding agreements disclosed.

About Mink Therapeutics Inc
Market cap
$58M
1Y TSR
−22.9%
3Y TSR
−12.9%
Board grade
C-
Sector
Healthcare
CEO
Jennifer Buell
Last annual meeting: Jun 17, 2026 · View full Mink Therapeutics Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2026

 

 

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40908

82-2142067

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

149 Fifth Avenue

Suite 500

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 994-8250

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

INKT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

In response to recent investor inquiries regarding third-party postings concerning potential combination trials involving agenT-797, MiNK Therapeutics, Inc. (the “Company”) is providing the following clarification:

The Company is actively engaged in discussions with multiple parties regarding potential combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy, as well as potential strategic minority investments in the Company. The Company believes these discussions reflect growing interest in the Company’s platform, including its potential application in areas of significant unmet medical need such as critical illness.

The Company has not publicly disclosed any binding arrangements with respect to potential combination trials or strategic investments.

Forward-Looking Statements

This filing contains forward-looking statements within the meaning of the federal securities laws, including statements regarding potential combination trials or strategic investments for agenT-797. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law and acknowledges there can be no assurance that the Company will enter into any referenced binding agreements on favorable terms or at all.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

March 27, 2026

By:

/s/ Jennifer S. Buell

 

 

 

Jennifer S. Buell, Ph.D., Chief Executive Officer

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings IntelligenceSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Mink Therapeutics Inc (INKT)

Continue researching
Reference

Frequently asked questions

When did Mink Therapeutics Inc file this 8-K?
Mink Therapeutics Inc (INKT) filed this Current Report (Form 8-K) with the SEC on March 27, 2026. The accession number assigned by EDGAR is 0001193125-26-127931.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
MiNK clarifies ongoing discussions with multiple parties on potential agenT-797 combination trials and strategic minority investments; no binding agreements disclosed. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Mink Therapeutics Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Mink Therapeutics Inc has filed under CIK 1840229, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer